New strategies for vaccination and imunomodulation in NHL
New strategies for vaccination and imunomodulation in NHL
Knowledge of the genetic changes which occur in cancer cells is stimulating research aimed towards new therapies. Immunotherapeutic approaches, particularly antibody therapy, are already finding a place in treatment of hematological malignancies. Vaccination will build on experience in the field of infectious diseases, and it should be possible to design vehicles to deliver the expanding range of tumour antigens to the immune system. For DNA vaccines, fusion genes have the potential to activate and direct immune effector pathways. One candidate antigen for B-cell malignancies is the clonal idiotypic immunoglobulin and we have designed a fusion vaccine encoding idiotypic sequence fused to a sequence from a powerful antigen from tetanus toxin. This promotes protective immunity against lymphoma in models, and is now in clinical trial. Our challenge is to bring patients into remission without significant damage to immune capacity. Another is to rethink the nature of clinical trials so that more pilot studies of efficacy can be carried out. There is no evidence so far of toxicity due to injection of DNA, but for antigens which are expressed by normal cells, the line between attack on tumour and autoimmunity will have to be carefully drawn.
B-cell tumors, DNA vaccines, immunotherapy, idiotypic immunoglobulin, variable region genes
B132-B134
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Zhu, Delin
49eeb78f-f607-4079-80b3-45574dc41fa5
Rice, Jason
d58d4fcd-8dc0-4599-bf96-62323d579227
2001
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Zhu, Delin
49eeb78f-f607-4079-80b3-45574dc41fa5
Rice, Jason
d58d4fcd-8dc0-4599-bf96-62323d579227
Stevenson, Freda K., Zhu, Delin and Rice, Jason
(2001)
New strategies for vaccination and imunomodulation in NHL.
Annals of Hematology, 80 (Supplement 3), .
Abstract
Knowledge of the genetic changes which occur in cancer cells is stimulating research aimed towards new therapies. Immunotherapeutic approaches, particularly antibody therapy, are already finding a place in treatment of hematological malignancies. Vaccination will build on experience in the field of infectious diseases, and it should be possible to design vehicles to deliver the expanding range of tumour antigens to the immune system. For DNA vaccines, fusion genes have the potential to activate and direct immune effector pathways. One candidate antigen for B-cell malignancies is the clonal idiotypic immunoglobulin and we have designed a fusion vaccine encoding idiotypic sequence fused to a sequence from a powerful antigen from tetanus toxin. This promotes protective immunity against lymphoma in models, and is now in clinical trial. Our challenge is to bring patients into remission without significant damage to immune capacity. Another is to rethink the nature of clinical trials so that more pilot studies of efficacy can be carried out. There is no evidence so far of toxicity due to injection of DNA, but for antigens which are expressed by normal cells, the line between attack on tumour and autoimmunity will have to be carefully drawn.
This record has no associated files available for download.
More information
Published date: 2001
Keywords:
B-cell tumors, DNA vaccines, immunotherapy, idiotypic immunoglobulin, variable region genes
Identifiers
Local EPrints ID: 26611
URI: http://eprints.soton.ac.uk/id/eprint/26611
PURE UUID: 717dbb6d-fe1a-43cf-a72b-8ef3461bdd32
Catalogue record
Date deposited: 24 Apr 2006
Last modified: 23 Jul 2022 01:41
Export record
Contributors
Author:
Delin Zhu
Author:
Jason Rice
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
